In Vivo Pharmacodynamic Evaluation of NCI-H226 Cell Line Based Lung Cancer (CAT#: STEM-AE-0086-LGZ)

Introduction

Lung cancer is the most common primary malignant tumor of lung. Most lung cancer originates from the bronchial mucosal epithelium, so it is also called bronchial lung cancer. Lung cancer can spread around and even throughout the body. The distribution of lung cancer is more in the right lung than in the left lung, in the upper lobe than in the lower lobe, and cancer can occur from the main bronchus to the bronchioles. Originated from the main bronchus, bronchus lobar lung cancer, close to the hilum of the lung, known as central type lung cancer; Lung cancer originating below the bronchus of the lung segment, located in the surrounding part of the lung, known as peripheral lung cancer.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

In vivo activity is the gold standard for the evaluation of drug biological activity, and it is the first verification of non-human comprehensive activity. In vivo pharmacodynamic evaluation plays a decisive role in the confirmation of candidate molecules and the screening of clinical target indications, and is an indispensable link in the development of new drugs. We provide a variety of disease animal models including inflammation, immunity, metabolism, etc., to meet the needs of different new drug research and development projects of customers, and accept customized services.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.

Applications

Lung Cancer

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder

Notes

Oncology efficacy Service package:
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model

Other recommended products

In Vivo Pharmacodynamic Evaluation of B-hCB1 Mice (GPCR Humanized Mice) (CAT#: STEM-AE-0541-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hPD-L1/hSIRPA/hCD47 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0416-LGZ)
In Vivo Pharmacodynamic Evaluation of BT-549 Cell Line Based Breast Cancer (CAT#: STEM-AE-0015-LGZ)
In Vivo Pharmacodynamic Evaluation of SNU-16 Cell Line Based Gastric Cancer (CAT#: STEM-AE-0049-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCD39 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0192-LGZ)
In Vivo Pharmacodynamic Evaluation of SW626 Cell Line Based Ovary Cancer (CAT#: STEM-AE-0102-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hTNFR2/hTNFR1/hLTBR Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0291-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hHVEM MC38 Cells Induced Tumor Models (CAT#: STEM-AE-0173-LGZ)